Roles of Glycogen Synthase Kinase-3 in Alzheimer's Disease

From Pathology to Treatment Target

Hsing Cheng Liu, Sy Jye Leu, De Maw Chuang

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder with an unknown cause, and as of yet there is no effective treatment. The neuropathological hallmarks of AD include amyloid plaques and neurofibrillary tangle (NFT) deposits. There is evidentiary support for amyloid deposition being the primary influence driving AD pathogenesis, commonly referred to as the amyloid hypothesis of AD. But brain amyloid load is not correlated with AD severity; instead, NFT formation has been shown to be associated with disease progression. Therefore, advocates of the tau hypothesis strongly postulate that NFT accumulation is critical for neuronal loss and AD development. Hence, inhibition of NFT formation/accumulation is one of the treatment strategies to combat AD. NFTs consist of aggregations of paired helical hyperphosphorylated tau protein, one of the major microtubule-associated proteins. The hyperphosphorylation of tau impairs its normal maintenance function for cytoskeleton stability, and induces a toxic sequestration of normal tau and other microtubule-associated proteins. Glycogen synthase kinase-3 (GSK-3) is the main enzyme that phosphorylates tau, and an increase in GSK-3 activity has been observed in AD patients. GSK-3 inhibition by lithium, a major mood stabilizer that is used to treat bipolar disorder, has been shown to reduce tau phosphorylation and even decrease amyloid burden in the brain of AD animal models. This supports the notion of GSK-3 inhibition as a potential avenue for AD treatment.

Original languageEnglish
Pages (from-to)135-139
Number of pages5
JournalJournal of Experimental and Clinical Medicine(Taiwan)
Volume4
Issue number3
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Glycogen Synthase Kinase 3
Alzheimer Disease
Pathology
Neurofibrillary Tangles
Amyloid
Therapeutics
Microtubule-Associated Proteins
tau Proteins
Poisons
Amyloid Plaques
Brain Diseases
Cytoskeleton
Bipolar Disorder
Lithium
Neurodegenerative Diseases
Disease Progression
Animal Models
Maintenance
Phosphorylation

Keywords

  • Alzheimer's disease
  • Beta-amyloid
  • Glycogen synthase kinase-3
  • Lithium
  • Neurofibrillary tangle
  • Tau

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Roles of Glycogen Synthase Kinase-3 in Alzheimer's Disease : From Pathology to Treatment Target. / Liu, Hsing Cheng; Leu, Sy Jye; Chuang, De Maw.

In: Journal of Experimental and Clinical Medicine(Taiwan), Vol. 4, No. 3, 06.2012, p. 135-139.

Research output: Contribution to journalArticle

@article{c3f588497fb048ff82802bbccd1a1946,
title = "Roles of Glycogen Synthase Kinase-3 in Alzheimer's Disease: From Pathology to Treatment Target",
abstract = "Alzheimer's disease (AD) is a progressive neurodegenerative disorder with an unknown cause, and as of yet there is no effective treatment. The neuropathological hallmarks of AD include amyloid plaques and neurofibrillary tangle (NFT) deposits. There is evidentiary support for amyloid deposition being the primary influence driving AD pathogenesis, commonly referred to as the amyloid hypothesis of AD. But brain amyloid load is not correlated with AD severity; instead, NFT formation has been shown to be associated with disease progression. Therefore, advocates of the tau hypothesis strongly postulate that NFT accumulation is critical for neuronal loss and AD development. Hence, inhibition of NFT formation/accumulation is one of the treatment strategies to combat AD. NFTs consist of aggregations of paired helical hyperphosphorylated tau protein, one of the major microtubule-associated proteins. The hyperphosphorylation of tau impairs its normal maintenance function for cytoskeleton stability, and induces a toxic sequestration of normal tau and other microtubule-associated proteins. Glycogen synthase kinase-3 (GSK-3) is the main enzyme that phosphorylates tau, and an increase in GSK-3 activity has been observed in AD patients. GSK-3 inhibition by lithium, a major mood stabilizer that is used to treat bipolar disorder, has been shown to reduce tau phosphorylation and even decrease amyloid burden in the brain of AD animal models. This supports the notion of GSK-3 inhibition as a potential avenue for AD treatment.",
keywords = "Alzheimer's disease, Beta-amyloid, Glycogen synthase kinase-3, Lithium, Neurofibrillary tangle, Tau",
author = "Liu, {Hsing Cheng} and Leu, {Sy Jye} and Chuang, {De Maw}",
year = "2012",
month = "6",
doi = "10.1016/j.jecm.2012.04.001",
language = "English",
volume = "4",
pages = "135--139",
journal = "Journal of Experimental and Clinical Medicine",
issn = "1878-3317",
publisher = "Elsevier Taiwan LLC",
number = "3",

}

TY - JOUR

T1 - Roles of Glycogen Synthase Kinase-3 in Alzheimer's Disease

T2 - From Pathology to Treatment Target

AU - Liu, Hsing Cheng

AU - Leu, Sy Jye

AU - Chuang, De Maw

PY - 2012/6

Y1 - 2012/6

N2 - Alzheimer's disease (AD) is a progressive neurodegenerative disorder with an unknown cause, and as of yet there is no effective treatment. The neuropathological hallmarks of AD include amyloid plaques and neurofibrillary tangle (NFT) deposits. There is evidentiary support for amyloid deposition being the primary influence driving AD pathogenesis, commonly referred to as the amyloid hypothesis of AD. But brain amyloid load is not correlated with AD severity; instead, NFT formation has been shown to be associated with disease progression. Therefore, advocates of the tau hypothesis strongly postulate that NFT accumulation is critical for neuronal loss and AD development. Hence, inhibition of NFT formation/accumulation is one of the treatment strategies to combat AD. NFTs consist of aggregations of paired helical hyperphosphorylated tau protein, one of the major microtubule-associated proteins. The hyperphosphorylation of tau impairs its normal maintenance function for cytoskeleton stability, and induces a toxic sequestration of normal tau and other microtubule-associated proteins. Glycogen synthase kinase-3 (GSK-3) is the main enzyme that phosphorylates tau, and an increase in GSK-3 activity has been observed in AD patients. GSK-3 inhibition by lithium, a major mood stabilizer that is used to treat bipolar disorder, has been shown to reduce tau phosphorylation and even decrease amyloid burden in the brain of AD animal models. This supports the notion of GSK-3 inhibition as a potential avenue for AD treatment.

AB - Alzheimer's disease (AD) is a progressive neurodegenerative disorder with an unknown cause, and as of yet there is no effective treatment. The neuropathological hallmarks of AD include amyloid plaques and neurofibrillary tangle (NFT) deposits. There is evidentiary support for amyloid deposition being the primary influence driving AD pathogenesis, commonly referred to as the amyloid hypothesis of AD. But brain amyloid load is not correlated with AD severity; instead, NFT formation has been shown to be associated with disease progression. Therefore, advocates of the tau hypothesis strongly postulate that NFT accumulation is critical for neuronal loss and AD development. Hence, inhibition of NFT formation/accumulation is one of the treatment strategies to combat AD. NFTs consist of aggregations of paired helical hyperphosphorylated tau protein, one of the major microtubule-associated proteins. The hyperphosphorylation of tau impairs its normal maintenance function for cytoskeleton stability, and induces a toxic sequestration of normal tau and other microtubule-associated proteins. Glycogen synthase kinase-3 (GSK-3) is the main enzyme that phosphorylates tau, and an increase in GSK-3 activity has been observed in AD patients. GSK-3 inhibition by lithium, a major mood stabilizer that is used to treat bipolar disorder, has been shown to reduce tau phosphorylation and even decrease amyloid burden in the brain of AD animal models. This supports the notion of GSK-3 inhibition as a potential avenue for AD treatment.

KW - Alzheimer's disease

KW - Beta-amyloid

KW - Glycogen synthase kinase-3

KW - Lithium

KW - Neurofibrillary tangle

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=84862023165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862023165&partnerID=8YFLogxK

U2 - 10.1016/j.jecm.2012.04.001

DO - 10.1016/j.jecm.2012.04.001

M3 - Article

VL - 4

SP - 135

EP - 139

JO - Journal of Experimental and Clinical Medicine

JF - Journal of Experimental and Clinical Medicine

SN - 1878-3317

IS - 3

ER -